Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.
Republicans loved the made-for-television moments in President Trump's third State of the Union speech as he made his case for reelection. Democrats did not.
Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.
Lawmakers Thursday passed a bill to rein in drug costs. President Trump has vowed to veto it. But the plan shares a lot with other bipartisan efforts. Here's how it would work.
It was a tough week for the agency in charge of implementing Trump's ambitious plans to reduce drug costs. The administration rolled back one plan and had another shot down in court.
Certain high-cost drugs are straining state budgets. A new deal approved Wednesday allows Louisiana to spend a fixed amount for unlimited access to a costly cure. Other states may try to follow suit.
The government wants consumers to have sticker shock about drug prices. A new rule requires list prices be displayed in TV ads. Patients advocates are not sure it will do much to lower prices.
Fatima Suleman, a professor of pharmaceutical sciences, hopes that WHO's Fair Pricing Forum can help lower drug costs — and benefit drug manufacturers.
The Senate Finance Committee will hear Tuesday from executives from the biggest pharmacy benefit managers. Confidential rebates paid to the PBMs are expected to draw scrutiny.
As congressional lawmakers continue to turn up the heat on drugmakers, insurers and middlemen over the price of many medicines, one player says it will limit patients' share of the cost of insulin.
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better.
The Indianapolis-based drugmaker said Monday that it would offer a generic version of Humalog insulin, one of its best-selling medicines. The move could help blunt criticism about high prices.
Critics question claims by federal officials that CanaRX jeopardizes patient safety. Many U.S. companies, cities, counties and school districts rely on the firm to help employees get cheaper medicine.
A new poll by the Kaiser Family Foundation shows that many people struggle to pay for medicines and that a majority of Americans would welcome a range of government interventions to lower prices.
Senators called pharmaceutical industry leaders to account for the high costs of medicine during a Senate hearing. The executives deflected blame to insurance companies and middlemen.
A Senate hearing on Tuesday featuring pharmaceutical executives will tackle many issues raised in the historic Kefauver hearings, which led to tougher drug regulation. High prices remain a concern.
The president's State of the Union address laid out a series of goals, including lowering prescription prices, pursuing an end to the HIV epidemic and increasing research for childhood cancers.
Pharmacy benefit managers are the focus of proposed regulations that could reduce drug costs for seniors and cut profits for middlemen. It could set a precedent for the broader market.
A recent study shows the cost of brand-name drugs is rising — not because of expensive new therapies entering the market but because manufacturers are raising prices on existing drugs.
Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life and death issue. Now a grassroots movement is pushing for change.
An administration proposal would link what Medicare pays for certain drugs administered in hospitals and doctor's offices to the prices paid in Europe and other advanced economies.
A former health insurance executive has made it her mission to bring down high health care costs. She's demanding a better deal for employers — and the workers whose care they pay for.
A consortium of hospital systems and three foundations is moving ahead with a nonprofit drugmaker that would produce some of the generic medicines health care facilities need the most.
